Announcement; Launch of 5-HT3 Receptor Antagonist “Aloxi(R) I.V. infusion bag 0.75mg”

ZOSYN®, an Injectable Antibiotic Combination Product Receives an Approval for Peritonitis, Intra-abdominal Abscess,Cholecystitis, and Cholangitis

Clinical Trial (JASPAC 01) of TS-1 for Resected Pancreatic Cancer

Results of a Phase II Clinical Trial for the Novel Antitumor Agent TAS-102 Posted on the Electronic Edition of The Lancet Oncology

Taiho and Faes Farma (Spain) Enter into a License Agreement on Anti- Allergy Agent

Business Partnership regarding Breakthrough Cancer Pain Reliever "OVF"

Launch of Histamine H2 Receptor Antagonist PROTECADIN OD Tablets (Orally Disintegrating Tablet)

Phase III Clinical Trial (CATS TRIAL) for Non-small-cell Lung Cancer Non-inferiority of TS-1 + Cisplatin Treatment Verified Presented to the American Society of Clinical Oncology (ASCO)

Taiho Pharmaceutical Announces the Start of a Global Phase III Clinical Trial in Metastatic Colorectal Cancer with the Novel Antitumor Agent TAS-102

Distributor change for Lentinan I.V. Infusion 1 mg “Ajinomoto”, an anti-tumor agent

Anti-Cancer Drug Teysuno® has been launched in the United Kingdom

Taiho Pharmaceutical’s Anticancer Agent TS-1 Approved for Market in Hong Kong

Termination of co-development of a β3-adrenoceptor agonist

Taiho Pharmaceutical's Anticancer Agent TS-1 Approved for Market in Thailand

Taiho Pharmaceutical Co., Ltd. and Nordic Group BV have launched Anti-Cancer Drug Teysuno™ in Sweden, Denmark, Norway and Finland

Licensing Agreement Cancelled for NST-141 Agent for Pruritus in Atopic Dermatitis

ABRAXANE® I.V. Infusion 100 mg Application Submitted for Approval of Additional Indications in Japan